For von Willebrand disease Type 2 or Type 3, which product can be used?

• A. Desmopressin
• B. Factor VII concentrate
• C. Platelet transfusion
• D. Fresh frozen plasma

Answer: (B)

The key idea is replacement of the deficient von Willebrand factor. In von Willebrand disease types 2 and 3, the problem is insufficient or dysfunctional vWF, so the needed treatment is a product that directly provides von Willebrand factor (often together with factor VIII) to restore normal platelet adhesion and clot formation. Desmopressin can help in some milder forms (more typical for type 1 and some type 2 variants) by releasing endogenous vWF, but it isn’t reliably effective in type 2 or especially type 3 and can be ineffective or unsafe in certain subtypes. Platelet transfusion and fresh frozen plasma are less ideal because they’re less predictable and carry more variability or risk, and a concentrate that contains vWF is the targeted, most reliable therapy. In practice, this means using a von Willebrand factor–containing concentrate (often with FVIII) for these patients.